Diabetes FriendsVideo
Categories
- Allergy
- Alzheimer's Disease
- Arthritis
- Asthma
- Breast Cancer
- Cardio Health
- Cholesterol
- Cold and Flu
- Colon Cancer
- Diabetes
- Dieting
- Epilepsy
- Hair Loss
- Headache
- Heartburn
- HIV & AIDS
- Kidney Health
- Leukemia
- Lung Cancer
- Lymphoma
- Multiple Sclerosis
- Men's Health
- Mental Health
- Nutrition
- Osteoporosis
- Parkinson's Disease
- Prostate Health
- Skin Health
- Sleep Disorders
- Women's Health
- General
Zoledronic Acid Protects Bones of Women Getting Breast Cancer Treatment
Posted on 08/19/2008, 19:00
By -- Robert Preidt
Drug countered effect of endocrine therapy in premenopausal patients, study finds
TUESDAY, Aug. 19 (HealthDay News) -- Zoledronic acid prevents bone loss in breast cancer patients undergoing endocrine therapy and improves bone mineral density after treatment, according to an Austrian study.
Adjuvant endocrine therapy is widely used in patients with endocrine-responsive early breast cancer, but the treatment causes bone loss in premenopausal women.
This study by Michael Gnant of the Medical University of Vienna, General Hospital Vienna, and colleagues included 404 premenopausal breast cancer patients randomly assigned to receive three years of either goserelin plus tamoxifen with or without zoledronic acid or goserelin plus anastrozole with or without zoledronic acid.
The women's bone mineral density was measured at the start of the study and again at six, 12, 36 and 60 months.
After three years of treatment, the women who received endocrine therapy alone (199) showed significant loss of bone mineral density (BMD). Partial recovery of BMD was noted at five years (two years after completion of endocrine therapy), but their BMD was still lower than it was at the start of the study.
BMD among the women who received zoledronic acid (Zometa) while undergoing endocrine therapy (205) remained stable at three years and increased at five years.
The study was published online and was expected to be in the September print issue of The Lancet Oncology.
"The findings presented here offer important information related to bone health for premenopausal women undergoing adjuvant endocrine therapy," Gnant wrote.
More information
Breastcancer.org has more about chemotherapy for breast cancer.
SOURCE: The Lancet, news release, Aug. 20, 2008
Copyright © 2008 ScoutNews, LLC. All rights reserved.
BigHealthTree.com Disclaimer
Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.
Exercise Stroke
Diabetes Cancer Drug
ADHD Toys
HPV Cancer Data
Hand Rejuvenation
PMS Linked to Smoking
Veggies Cosmetics
Scent Memories
Prescription Addiction
Autism Room
Breakfast on the Run
Diabetes
Orange Decongestant
Wii Childrens Hosptial

Comments (0):
Be the first to comment on this article.
Post a comment